Phaseline

Targets › CD20

CD20 (B-lymphocyte antigen CD20): drug programs, companies and trials

41 programs from 37 companies in 60 trials: 41 Phase 1, 10 Phase 3, 9 Phase 2; Oncology, Immunology, Neurology; next expected readout Dec 2026.

B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. (UniProt, P11836)

Open in Phaseline: the race on CD20, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Junshi Bioscience Co., Ltd.JS203 for Injection
CD20 x CD3 bispecific antibody
CD20Phase 3Diffuse Large B-Cell Lymphoma; B-cell Non-Hodgkin's Lymphoma; Relapsed/Refractory B-cell Non-Hodgkin's LymphomaDec 2026
AstraZenecasurovatamig (AZD0486)
Bispecific monoclonal antibody targeting CD20 and CD3E
CD19, CD3E, CD20Phase 3Large B-cell Lymphoma; Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV; Untreated Follicular Lymphoma; B-cell Non-Hodgkin Lymphoma …Jan 2028
Fondazione Italiana Linfomi - ETSObinutuzumab-CHOP (G-CHOP)
glycoengineered anti-CD20 antibody combined with cyclophosphamide, doxorubicin, vincristin
CD20Phase 3Follicular LymphomaJul 2028
Fondazione Italiana Linfomi - ETSObinutuzumab-bendamustine (G-Benda)
glycoengineered anti-CD20 monoclonal antibody combined with alkylating agent bendamustine
CD20, DNAPhase 3Follicular LymphomaJul 2028
Fondazione Italiana Linfomi - ETSRituximab-bendamustine (R-Benda)
anti-CD20 monoclonal antibody combined with alkylating agent bendamustine
CD20, DNAPhase 3Follicular LymphomaJul 2028
BiocadBCD-281
anti-CD20 monoclonal antibody
CD20Phase 3Relapsing-remitting Multiple Sclerosis (RRMS)Dec 2028
Lyell ImmunopharmaRondecabtagene autoleucel (ronde-cel)
Dual-targeting CAR T-cell therapy targeting CD19 and CD20
CD19, CD20Phase 3Large B-cell Lymphoma; Relapsed Non-Hodgkin LymphomaDec 2028
University Hospital FreiburgR-MTX/AraC (MARTA) induction followed by consolidating HCT-ASCT
CD20-targeted immunochemotherapy with high-dose methotrexate-based induction followed by h
CD20Phase 3Primary Central Nervous System LymphomaAug 2029
Shanghai Jiaolian Drug Research and DevelopmentB007
Anti-CD20 monoclonal antibody
CD20Phase 2Generalized Myasthenia Gravis; Pemphigus; Primary Membranous NephropathyDec 2026
Institute of Hematology & Blood Diseases Hospital, ChinaCAR-T cells (single-target or dual-target directed against CD19, CD20, and/or CD
CAR-T cell therapy targeting CD19, CD20, and/or CD22
CD19, CD20, CD22Phase 2Relapsed or Refractory Aggressive B-cell LymphomaMay 2027
Daihong LiuPolymer-Lipid Nanoparticle-Mediated Delivery of CD19/CD20 Dual-Targeting InViVoC
CAR-T cell therapy delivering dual-targeting CD19/CD20 CAR mRNA via polymer-lipid nanopart
CD19, CD20Phase 2B-cell Lymphoma RefractoryAug 2027
Shanghai Chia Tai Tianqing Pharmaceutical Technology DevelopmentTQB2825 Injection
CD3/CD20 bispecific antibody
CD3, CD20Phase 2Diffuse Large Cell B-lymphomaFeb 2028
Chia Tai Tianqing Pharmaceutical GroupTQB2825 injection
CD20/CD3 bispecific antibody
CD20, CD3Phase 1Diffuse Large B Cell LymphomaDec 2026
Cho PharmaCHO-H01
Anti-CD20 monoclonal antibody
CD20Phase 1Non-Hodgkin LymphomaDec 2026
Ohio State University Comprehensive Cancer CenterAutologous Anti-CD19/CD20/CD22 CAR T-cells
Multi-targeted CAR-T cell therapy targeting CD19, CD20, and CD22
CD19, CD20, CD22Phase 1Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveDec 2026
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCT1192
Dual CD19/CD20-targeting CAR-T cell therapy
CD19, CD20Phase 1Systemic Lupus Erythematosus (SLE)Dec 2026
Medical College of WisconsinCAR-20/19-T cells
Chimeric antigen receptor T cells targeting CD20 and CD19, expanded with IL-7/IL-15
CD20, CD19Phase 1Non Hodgkin Lymphoma (NHL)Feb 2027
GenomeFrontier Therapeutics TWGF-CART01
CD20/CD19-targeting CAR T cell therapy
CD20, CD19Phase 1Diffuse Large B Cell Lymphoma RelapsedMar 2027
Adicet TherapeuticsADI-001
Anti-CD20 CAR-T cell therapy
CD20Phase 1Rheumatoid Arthritis (RA)Mar 2027
Hebei Senlang BiotechnologyAutologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
Multi-target CAR-T cells targeting CD19, CD20, and CD22
CD19, CD22, CD20Phase 119 and 22+ B Cell Hematologic TumorsMar 2027
Johnson & Johnson (Janssen)JNJ-80948543
T-cell redirecting trispecific antibody against CD79b, CD20, and CD3
CD79B, CD20, CD3Phase 1Lymphoma, Non-HodgkinMar 2027
Shanghai AbelZetaPrizloncabtagene autoleucel
4-1BB bispecific CAR-T cell targeting CD19 and CD20
CD19, CD20Phase 1Relapsed/Refractory Large B-Cell LymphomaMar 2027
Chinese PLA General HospitalSL1617 Injection
In vivo CD19/CD20-targeted CAR T-cell immunotherapy utilizing engineered lentiviral vector
CD19, CD20Phase 1B-cell LymphomaApr 2027
AstraZenecaAZD5492
CD8/TCR-based T-cell engaging antibody targeting CD20
CD20Phase 1Systemic Lupus Erythematosus; B-cell MalignanciesMay 2027
The First Affiliated Hospital with Nanjing Medical UniversityCD19/CD20 Dual-Target in vivo CAR-T Lentiviral product
Dual-target CAR-T cell therapy targeting CD19 and CD20
CD19, CD20Phase 1Relapsed/Refractory B-cell MalignanciesJun 2027
Sumithira VasuAnti-CD19/CD20/CD22 CAR T-Cells
Multi-targeted CAR-T cell therapy targeting CD19, CD20, and CD22
CD19, CD20, CD22Phase 1Recurrent Acute Lymphoblastic LeukemiaJul 2027
CellectisUCART20x22
Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptor
CD20, CD22Phase 1B-cell Non-Hodgkin Lymphoma (B-NHL)Aug 2027
Hinge BioHB2198
Tetravalent bispecific anti-CD19/CD20 antibody with dual Fc domains
CD19, CD20Phase 1Healthy Volunteer; Systemic Lupus Erthematosus (SLE)Oct 2027
Shenzhen University General HospitalCD19/CD20 CAR/TRuC-T
Dual-targeted CAR/TRuC T-cell therapy against CD19 and CD20
CD19, CD20Phase 1Relapsed/Refractory B-cell LymphomaDec 2027
Tianjin Medical University Cancer Institute and HospitalLUCAR-G39D
Dual-targeted CAR-T cell therapy targeting CD19 and CD20
CD19, CD20Phase 1B-Cell Non-Hodgkin Lymphoma-RecurrentJun 2028
Sun Yat-sen UniversityR-CMOP Regimen
Rituximab (anti-CD20 antibody) combined with cyclophosphamide, liposomal mitoxantrone, vin
CD20Phase 1Diffuse Large B-Cell LymphomaAug 2028
National Cancer Institute (NCI)Anti-CD19 and anti-CD20 bicistronic CAR T cells
bicistronic CAR T cells targeting CD19 and CD20
CD19, CD20Phase 1Chronic Lymphocytic LeukemiaDec 2028
Poseida TherapeuticsP-CD19CD20-ALLO1
Allogeneic CAR-T cells targeting CD19 and CD20
CD19, CD20Phase 1Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedMar 2029
AvenCell TherapeuticsAllo-QuadCAR01-T
Allogeneic CAR-T cell therapy targeting CD19/CD20
CD19, CD20Phase 1Lymphoma Diffuse Large B-cellApr 2029
RocheP-CD19CD20-ALLO1
allogeneic CAR-T cell therapy targeting CD19 and CD20
CD19, CD20Phase 1Multiple SclerosisAug 2032
Fred Hutchinson Cancer CenterCD20-specific CAR T-cell therapy
anti-CD20 CAR-T cell therapy
CD20Phase 1Recurrent B-Cell Non-Hodgkin LymphomaMar 2039
Shenzhen University General HospitalCD19/CD20-CAR.p40-T
Dual-targeting CD19/CD20 chimeric antigen receptor T cell therapy
CD19, CD20Phase 1Relapsed/Refractory B-cell Lymphoma–
Han weidongDecitabine-primed Tandem CAR19/20 engineered T cells
Tandem CAR-T cell therapy targeting CD19 and CD20, primed with decitabine
CD19, CD20Phase 1Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma–
Guangzhou ExcelmabEX103
CD3 and CD20 bispecific monoclonal antibody
CD3E, CD20Phase 1CD20-positive Non-Hodgkin Lymphoma–
Gilead SciencesINT2104
CD20-targeting CAR (chimeric antigen receptor) delivered by lentiviral vector
CD20Phase 1Lymphomas Non-Hodgkin's B-Cell–
Zhejiang Teruisi PharmaceuticalTRS005
Anti-CD20 monoclonal antibody-MMAE antibody-drug conjugate
CD20, MMAEPhase 1CD20-positive B-cell Non-Hodgkin Lymphoma–

Conditions

Lymphoma, Non-Hodgkin (3) Primary Membranous Nephropathy (3) Follicular Lymphoma (3) Large B-cell Lymphoma (2) B-cell Non-Hodgkin Lymphoma (2) Relapsed/Refractory B-cell Lymphoma (2) Diffuse Large B-Cell Lymphoma (2) Generalized Myasthenia Gravis (1) Pemphigus (1) Relapsed Non-Hodgkin Lymphoma (1) Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV (1) Untreated Follicular Lymphoma (1)

Modalities

mixed (13), small molecule (12), other (9), antibody (4), protein or peptide (2)

Companies

Fondazione Italiana Linfomi - ETS (3) AstraZeneca (2) Shenzhen University General Hospital (2) Johnson & Johnson (Janssen) (1) Shanghai Jiaolian Drug Research and Development (1) Lyell Immunopharma (1) Daihong Liu (1) Zhejiang Teruisi Pharmaceutical (1) Institute of Hematology & Blood Diseases Hospital, China (1) AvenCell Therapeutics (1) Adicet Therapeutics (1) Cellectis (1) National Cancer Institute (NCI) (1) Medical College of Wisconsin (1) Fred Hutchinson Cancer Center (1) Chinese PLA General Hospital (1) The First Affiliated Hospital with Nanjing Medical University (1) Sun Yat-sen University (1) Biocad (1) Han weidong (1)

Related targets

CD19 (22) CD22 (5) CD3 (3) CD3E (2) DNA (2) CD79B (1) MMAE (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.